Published in Br J Haematol on February 01, 1976
E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther (2013) 1.28
The prostanoids in hemostasis and thrombosis: a review. Am J Pathol (1980) 0.83
Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders. J Aging Res (2012) 0.79
Damage control: Harnessing prostaglandin E2 as a potential healing factor of tissue injuries. Genes Dis (2015) 0.76
Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease. Thromb Res (2015) 0.75
Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol (1971) 7.75
Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet (1967) 5.38
The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest (1968) 3.66
Parallel assay of prostaglandin-like activity in rat inflammatory exudate by means of cascade superfusion. J Pharm Pharmacol (1969) 3.59
The 'subcortical dementia' of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry (1974) 3.48
Molecular Cloning of Osmotin and Regulation of Its Expression by ABA and Adaptation to Low Water Potential. Plant Physiol (1989) 3.28
Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest (1973) 2.94
Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. J Clin Invest (1973) 2.71
Decreased adhesion of platelets to subendothelium in von Willebrand's disease. J Lab Clin Med (1974) 2.44
Platelet physiology and abnormalities of platelet function (first of two parts). N Engl J Med (1975) 2.31
Cutaneous reactions to intradermal prostaglandins. Br J Pharmacol (1971) 2.27
Studies of the release from human platelets of the growth factor for cultured human arterial smooth muscle cells. Circ Res (1978) 2.14
An enzymatic mechanism for the antithrombotic and antihemostatic actions of aspirin. Science (1974) 2.08
An endoperoxide aggregator (Lass), formed in platelets in response to thrombotic stimuli: purification, identification and unique biological significance. Prostaglandins (1974) 2.02
Preventing sudden infant deaths--the slow diffusion of an idea. Health Policy (1996) 2.01
Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. Am J Med (1974) 1.86
Transient arthritis after rubella vaccination. Am J Dis Child (1969) 1.86
Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest (1977) 1.85
Platelet physiology and abnormalities of platelet function (second of two parts). N Engl J Med (1975) 1.69
Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem (1989) 1.63
Separation of sub-units of antihemophilic factor (AHF) by agarose gel chromatography. Thromb Diath Haemorrh (1972) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Formation and release of prostaglandins by platelets in response to thrombin. Br J Pharmacol (1970) 1.59
Molecular forms of antihaemophilic globulin in plasma, cryoprecipitate and after thrombin activation. Br J Haematol (1970) 1.57
Isolation of a chemical trigger for thrombosis. Prostaglandins (1974) 1.57
Changing life expectancy in central Europe: is there a single reason? J Public Health Med (1996) 1.54
Secretable storage pools in platelets. Annu Rev Med (1979) 1.49
Von Willebrand factor: dissociation from antihemophilic factor procoagulant activity. Science (1973) 1.49
Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. The THROMBO Investigators. Am J Cardiol (2000) 1.47
Aspirin--a dangerous drug? JAMA (1974) 1.47
Interaction between prostaglandins E and F given intradermally in the rat. Br J Pharmacol (1971) 1.47
Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate--dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. J Lab Clin Med (1978) 1.46
Fibrinogen and platelets in the primary arrest of bleeding. Studies in two patients with congenital afibrinogenemia. N Engl J Med (1971) 1.46
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand disease. Blood (1978) 1.39
ERalpha gene expression in human primary osteoblasts: evidence for the expression of two receptor proteins. Mol Endocrinol (2001) 1.39
Thrombogenic factors and recurrent coronary events. Circulation (1999) 1.38
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood (1979) 1.33
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Children and adults as intuitive scientists. Psychol Rev (1989) 1.31
Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med (1982) 1.26
Correction of the platelet abnormality in von Willebrand's disease by cryoprecipitate. Am J Med (1972) 1.25
Studies of platelet function and proteins in 3 patients with Glanzmann's thrombasthenia. J Lab Clin Med (1968) 1.24
Simplified thin-layer chromatography of prostaglanding in biological extracts. Br J Pharmacol (1970) 1.24
Hereditary defect in the platelet release reaction caused by a deficiency in the storage pool of platelet adenine nucleotides. Br J Haematol (1970) 1.23
Further evidence for a deficient storage pool of adenine nucleotides in platelets from some patients with thrombocytopathia--"storage pool disease". Blood (1972) 1.23
Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb-IIIa, Ib, and storage granules. Blood (1986) 1.21
Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion. J Clin Invest (1984) 1.20
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
A familialdefect in platelet function associated with imapired release of adenosine diphosphate. N Engl J Med (1969) 1.18
A new potential mediator of arterial thrombosis whose biosynthesis is inhibited by aspirin. Prostaglandins (1973) 1.17
Platelet membrane glycoproteins in thrombasthenia, Bernard-Soulier syndrome, and storage pool disease. J Lab Clin Med (1979) 1.17
A congenital defect in platelet prostaglandin production associated with impaired hemostasis in storage pool disease. Prostaglandins (1973) 1.17
Dihomo-gamma-linolenate suppresses platelet aggregation when administered in vitro or in vivo. Prostaglandins (1974) 1.16
Platelet aggregation, adhesion and adenosine diphosphate release in thrombopathia (platelet factor 3 deficiency). A comparison with Glanzmann's thrombasthenia and von Willebrand's disease. Am J Med (1967) 1.16
Inhibition of intestinal tone and prostaglandin synthesis by 5,8,11,14 tetraynoic acid. Br J Pharmacol (1972) 1.16
Isolated deficiency of platelet procoagulant activity. Am J Med (1979) 1.15
Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol (1998) 1.14
Search for a supersymmetric partner to the top quark in final states with jets and missing transverse momentum at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.13
Red blood cells: their dual role in thrombus formation. Science (1980) 1.13
Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects. J Clin Invest (1986) 1.13
Thrombocytopathia due to abnormalities in platelet release reaction--studies on six unrelated patients. Blood (1972) 1.12
Proceedings: Thrombolytic and anti-thrombotic properties of dihomo-gamma-linolenate in vitro. Br J Pharmacol (1975) 1.11
Antithrombotic potential of dihomo-gamma-linolenic acid in man. Br Med J (1977) 1.10
Indocyanine green angiographic features of pathologic myopia. Am J Ophthalmol (1996) 1.10
Open channel block of NMDA receptor responses evoked by tricyclic antidepressants. Neuron (1989) 1.09
Repeated injection of prostaglandin E2 in rat paws induces chronic swelling and a marked decrease in pain threshold. Prostaglandins (1973) 1.08
Dependence of human platelet functional responses on divalent cations: aggregation and secretion in heparin- and hirudin-anticoagulated platelet-rich plasma and the effects of chelating agents. Thromb Haemost (1981) 1.07
Search for tb resonances in proton-proton collisions at √s=7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.07
Editorial: Platelet function tests and their interpretation. J Lab Clin Med (1976) 1.06
Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease. J Lab Clin Med (1983) 1.06
Von Willebrand's disease--diagnostic criteria. Blood (1968) 1.06
Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion. Blood (1985) 1.05
Search for a light Higgs boson decaying to long-lived weakly interacting particles in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.05
Psychopharmacology and mental retardation: a 10 year review (1990-1999). Res Dev Disabil (2000) 1.04
Studies of platelet 5-hydroxytryptamine (serotonin) in storage pool disease and albinism. J Clin Invest (1974) 1.03
Retracted Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci U S A (1996) 1.03
Effect of pressure ulcers on the survival of long-term care residents. J Gerontol A Biol Sci Med Sci (1997) 1.03
Antiplatelet therapy (first of two parts). N Engl J Med (1978) 1.02
Content and thrombin-induced release of acid hydrolases in gel-filtered platelets from patients with storage pool disease. Blood (1975) 1.02
Properties of the platelet retention (von Willebrand) factor and its similarity to the antihemophilic factor (AHF). Blood (1973) 1.01
Communicable disease outbreaks involving more than one country: systems approach to evaluating the response. BMJ (2001) 1.01
Actions and interactions of prostaglandins administered intradermally in rat and in man. Br J Pharmacol (1969) 1.00
Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol (2000) 0.99
Search for supersymmetry in events with three leptons and missing transverse momentum in √[s]=7 TeV pp collisions with the ATLAS detector. Phys Rev Lett (2012) 0.99
Inhibition of intestinal tone, motility and prostaglandin biosynthesis by 5,8,11,14-eicosatetraynoic acid (TYA). Prostaglandins (1974) 0.98
Thromboembolism--a continuing challenge. N Engl J Med (1970) 0.97
Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder. Blood (1985) 0.97
The effect of shear rate on platelet interaction with subendothelium exposed to citrated human blood. Microvasc Res (1980) 0.96
Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Arteriosclerosis (1985) 0.95